A new clinical trial published in the journal Blood indicates that adding danicopan to existing C5 inhibitors, ravulizumab or eculizumab, effectively improves hemoglobin levels in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH causes severe anemia and blood complications due to intravascular and extravascular hemolysis. Many patients treated with C5 blockers remained anemic due to extravascular hemolysis. This study involved 86 participants, revealing that those receiving danicopan experienced significantly better hemoglobin levels and required fewer blood transfusions, highlighting its potential benefit in managing this rare blood disorder.
In the trial, participants receiving danicopan showed a significant improvement in hemoglobin levels, leading to fewer required blood transfusions.
The current clinical trial aimed to evaluate the safety and efficacy of adding danicopan, which blocks extravascular hemolysis, to C5 inhibitors.
Collection
[
|
...
]